Major Adverse Cardiovascular Event Outcomes in Patients With Obesity and Type 2 Diabetes Undergoing Medical Weight Management
No statistically significant differences in MACE risk were found between those receiving MWM versus UC; there was a trend towards fewer MACE events in those receiving MBS. These findings must be validated in future studies, given that more effective weight loss medications (e.g., semaglutide, tirzepatide) were not available.
Authors
- Carolyn T. Bramante (ORCID: https://orcid.org/0000-0001-5858-2080)
- Tasma Harindhanavudhi (ORCID: https://orcid.org/0000-0002-8631-4144)
- David M. Vock (ORCID: https://orcid.org/0000-0002-5459-9579)
- Eric S. Wise (ORCID: https://orcid.org/0000-0002-6471-9466)
- Eric M. Bomberg (ORCID: https://orcid.org/0000-0002-8037-4314)
- Katelyn Tessier (ORCID: https://orcid.org/0000-0002-5513-583X)
- Nirjhar Dutta (ORCID: https://orcid.org/0000-0001-9066-6452)
- Charles J. Billington (ORCID: https://orcid.org/0000-0002-9826-1860)
- Shalamar D. Sibley
- Jenna Langer
Institutions
- University of Minnesota (US)
- Cancer Research And Biostatistics (US)
- Minneapolis VA Health Care System (US)
- University of Minnesota Children's Hospital (US)
Publication Details
- Journal
- Cureus
- Published
- 2025-10-07
- DOI
- https://doi.org/10.7759/cureus.94070
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- University of Minnesota
- National Institutes of Health
- Masonic Cancer Center, University of Minnesota
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Center for Advancing Translational Sciences